08:19 AM EDT, 06/24/2024 (MT Newswires) -- Valneva (VALN) said Monday Health Canada has approved its single-dose vaccine, Ixchiq, for the prevention of disease caused by the chikungunya virus for individuals 18 years of age and older.

The vaccine maker said it plans to sell first doses in Canada in Q4.

The health agency's approval was based on a phase 3 study, which showed a 98.9% seroresponse rate at 28 days with a single vaccination.

The company's vaccine was approved by the US Food and Drug Administration in November 2023, and the European Medicines Agency has also recommended marketing authorization of the vaccine in Europe, a formal decision of which is expected in Q3.

Price: 7.59, Change: +0.67, Percent Change: +9.68